31 results about "Protein stabilization" patented technology

The present invention provides methods and compositions for protein stabilization, particularly the stabilization of polymerases in aqueous solutions with cationic surfactants. The present invention further provides cationic surfactants, including polyethoxylated amines, that stabilize thermostable and thermolabile enzymes in solution. These surfactants stabilize the activity of various enzymes, including thermostable DNA polymerases, thermolabile DNA polymerases and reverse transcriptases.

The invention provides a multi-bead assay system for a protein based assay comprising at least two different beads. The first bead comprises protein and a protein stabilization matrix. The first bead forms a first solution when dissolved in liquid, and the first solution permits a first activity level for the assay. The second bead comprises a potentiation bead matrix that when dissolved in the first solution forms a second solution that potentiates the protein based assay to achieve a second activity level that is higher than the first activity level.

This invention is a method of using a class of excipients for protein formulation to reduce and/or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated. This method has never been disclosed anywhere in the literature.

Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions not constituting part of the wall portion, and which contains a formulation of a protein. Also provided are new methods of storing proteinaceous compositions. In one aspect, the stored protein is characterized as having an amino-terminal γ-carboxyglutamic acid (Gla) domain with 9-12 Gla residues.

The invention provides an adjuvant used for vaccine. The adjuvant comprises alumina gel, levamisole or its derivative, and also polyacrylate. The invention also discloses a vaccine composition containing the adjuvant and an application thereof. The adjuvant can be used as the adjuvant for inactivated vaccine, and also can be used for preparing protein stabilization liquid. The vaccine composition containing the adjuvant can generate humoral immunity for human body and can generate cellular immunity, and can generate good immune response under condition of low antigen content and single immune, and can stabilize protein, degradation and irreversible change cannot be generated.

The invention discloses a preparation method of low-fluorine Euphasia superb protein base stock. The preparation method comprises the following steps of: 1, low-temperature autolysis: homogenizing fresh and alive Euphasia superb and treating through ultraviolet irradiation to realize autolysis; 2, protein extraction: adding water into homogenate, stirring and extracting, carrying out centrifugal separation to obtain an upper-layer liquid phase and precipitates; 3, protein stabilization: refrigerating the upper-layer liquid for storage or drying the upper-layer liquid before refrigerating the upper-layer liquid for storage; 4, protein preparation: thawing the refrigerated upper-layer liquid; adjusting pH value to 4.8-5.8 or heating for 10-30 minutes at 80-100 DEG C and then centrifuging to obtain precipitate products and carrying out spray drying to finally obtain the Euphasia superb protein base stock. The preparation method is simple to operate and is quite suitable for field operation on a fishing ship; through adoption of the preparation method, the protein recovery rate is up to 46%-51% and the fat recovery rate is up to 54%-60%; and in the prepared low-fluorine Euphasia superb protein base stock, the protein content is 70-78%/100g of dry base stock, the fat content is 25-31g/100g of dry base stock and the fluorine content is lower than 1.5 mcg./g of dry base stock.

The invention relates to a sterilization machine system for dairy and beverage and a sterilization technology and discloses a double tube type superhigh temperature sterilization machine system and asterilization technology. The invention comprises two sets of completely independent tubular type sterilization machine systems which share a set of vacuumizing degassing system and high pressure homogenization system. Each set of sterilization system includes a charging balance cylinder system, a pre-heating section, a protein stabilization section, a high temperature sterilization section, a cooling filling section, a cooling backflow section and a hot water circulation system. Two sets of sterilization machine systems are connected through a plurality of reversing valves and aseptic valvesto realize the seamless switching operation between two sets of systems, thus, achieving the uninterrupted production of the sterilization machine system so as to substantially improve the productionefficiency of the heat filling production line.

The present invention relates to the technical field of stabilizing proteins, in particular to the therapeutic aspects of protein stabilization. L-carnitine is a useful agent for stabilizing proteins, and in a particularly favourable aspect in proteins used in the medical field. In a preferred aspect, L-carnitine is used for protecting chaperone activity, and in the medical field for preserving the activity of altered chaperone proteins. In connection with this invention L-carnitine is used for the preparation of a medicament for the treatment of diseases due to altered chaperone proteins, such as eye diseases, in particular cataract.

A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.

A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from Pyrococcus furiosus (PfMBP). Unlike conventional protein stabilization methods that employ mutations and recombinations, the inventive approach does not require any modification on a target protein except for its connection with a hyperthermophilic protein scaffold. For that reason, target protein substrate specificity was largely maintained, which is often modified through conventional protein stabilization methods. The insertion was achieved through gene fusion by recombinant DNA techniques

Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and/or quantitative test for the deamidated products.

The present invention relates to protein chaperones, such as hybrid chaperones and methods for stabilizing proteins and protein activities comprising adding said protein chaperone to the protein. The present invention also provides a stabilized protein formulation comprising said protein chaperone associated with a protein and further relates to the enhancement of native chaperone activity by making hybrid protein chaperones.

There is provided a protein stabilizer for stably storing a protein in a solution. The protein may be an enzyme, an antibody, an enzyme-labeled antibody, or the like for a biochemical assay, etc. There is further provided a protein stabilization reagent comprising a protein-containing solution and the protein stabilizer dissolved therein. The protein stabilizer comprises a copolymer prepared by copolymerizing a monomer (a) of the following formula (1), a monomer (b) of the following formula (2), and a monomer (c) of the following formula (3).

The present invention relates to a protein-stabilized liquid formulation and provides: a composition for protein stabilization, the composition including a stabilizer and a surfactant and not including a buffer; a protein liquid composition including the composition for stabilization and a protein; and a method of producing a protein-stabilized liquid composition which uses the composition for stabilization.